Cartesian Therapeutics Files 8-K with Material Agreements & Officer Changes

Ticker: RNAC · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1453687

Cartesian Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCartesian Therapeutics, Inc. (RNAC)
Form Type8-K
Filed DateJul 2, 2024
Risk Levelmedium
Pages8
Reading Time9 min
Key Dollar Amounts$0.0001, $20, $130.0 million, $40,000, $6,000
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, officer-changes, equity-sale

TL;DR

Cartesian Therapeutics filed an 8-K detailing material agreements, equity sales, and leadership changes.

AI Summary

On July 1, 2024, Cartesian Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities, the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Additionally, amendments to articles of incorporation or bylaws, a change in fiscal year, and Regulation FD disclosures were noted, along with other events and financial statements.

Why It Matters

This 8-K filing indicates significant corporate actions, including new agreements and changes in leadership, which could impact the company's strategic direction and operational stability.

Risk Assessment

Risk Level: medium — The filing covers multiple significant events including material agreements, equity sales, and changes in directors/officers, suggesting potential volatility.

Key Players & Entities

  • Cartesian Therapeutics, Inc. (company) — Registrant
  • July 1, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 001-37798 (file_number) — SEC File Number

FAQ

What is the nature of the material definitive agreement entered into by Cartesian Therapeutics?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.

What specific changes occurred regarding directors or officers?

The filing reports on the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers.

Were there any unregistered sales of equity securities?

Yes, the filing explicitly mentions 'Unregistered Sales of Equity Securities' as an item reported.

Did Cartesian Therapeutics amend its articles of incorporation or bylaws, or change its fiscal year?

The filing lists 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as an item of information.

What is the company's primary industry classification?

Cartesian Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

Filing Stats: 2,324 words · 9 min read · ~8 pages · Grade level 11.3 · Accepted 2024-07-02 06:30:27

Key Financial Figures

  • $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC
  • $20 — Common Stock"), at a price per share of $20.00, and 2,937,903 shares (the "Preferre
  • $130.0 million — gregate purchase price of approximately $130.0 million. Each Preferred Share is convertible in
  • $40,000 — ch provides for (i) annual retainers of $40,000 for his Board service, $6,000 for his C
  • $6,000 — iners of $40,000 for his Board service, $6,000 for his Compensation Committee service,
  • $24.27 — e Option has an exercise price equal to $24.27 per share, the fair market value of a s

Filing Documents

01

Item 8.01. Other Events. On July 2, 2024, th e Company announced positive topline data from its Phase 2b trial of Descartes-08 in patients with myasthenia gravis. A copy of the slide presentation regarding the data is attached hereto as Exhibit 99.3. Item9.01.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 3.1 Certificate of Designation of Series B Non-Voting Convertible Preferred Stock 10.1 Securities Purchase Agreement, dated as of July 2, 2024, by and between Cartesian Therapeutics, Inc. and each purchaser identified on Annex A thereto 10.2 Form of Registration Rights Agreement 99.1 Press Release of Cartesian Therapeutics, Inc., dated July 2, 2024 99.2 Press Release of Cartesian Therapeutics, Inc., dated July 2, 2024 99.3 Cartesian Therapeutics, Inc. Phase 2b Data Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 2, 2024 CARTESIAN THERAPEUTICS, INC. By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.